CN110237062A - 一种以葡萄糖胺为调节剂的能够增强注意力的制剂 - Google Patents
一种以葡萄糖胺为调节剂的能够增强注意力的制剂 Download PDFInfo
- Publication number
- CN110237062A CN110237062A CN201910617552.XA CN201910617552A CN110237062A CN 110237062 A CN110237062 A CN 110237062A CN 201910617552 A CN201910617552 A CN 201910617552A CN 110237062 A CN110237062 A CN 110237062A
- Authority
- CN
- China
- Prior art keywords
- gucosamine
- regulator
- preparation
- raw material
- attention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 6
- 230000000116 mitigating effect Effects 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 5
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 claims 1
- 241000219094 Vitaceae Species 0.000 claims 1
- 241000219095 Vitis Species 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 229940097043 glucuronic acid Drugs 0.000 claims 1
- 235000021021 grapes Nutrition 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种以葡萄糖胺为调节剂的能够增强注意力的制剂。其是由谷氨酰胺、天门冬氨酸和葡萄糖胺组成，葡萄糖胺作为调节剂，能够缓和效应强度或调节效应时间。该制剂用以口服，提高目标人群或个体的注意力。具有依赖性低、作用缓和、使用安全的特点。
Description
技术领域
本发明公开了一种以葡萄糖胺为调节剂的能够增强注意力的制剂。其是由谷氨酰胺、天门冬氨酸和葡萄糖胺组成，葡萄糖胺作为调节剂，能够延长该制剂的效应时间，缓和制剂的刺激性。该制剂用以口服，提高目标人群或个体的注意力。具有依赖性低、作用缓和、使用安全的特点。本发明属于食品、药品加工领域。
背景技术
人类的学习或工作中，存在对事物的专注度的区别，即注意力不同。注意力影响长时记忆力，其受到大脑皮层神经活动的类型、生物化学代谢过程的影响。持续注意时间的下降，导致对事物不感兴趣、情绪急躁易怒、独立思考能力减弱，严重者会出现多动症。注意力的下降与神经衰弱和多动症的区别在于，前者表现为对事物专注性的保持能力暂时性降低，后者表现为对事物专注性的保持能力的器质性活动能力的持续性衰退。而多动症是注意力的不定性或转移性增加。有研究表明，脑活动主要由兴奋性神经递质如谷氨酸、天冬氨酸等和抑制性神经递质如γ-氨基丁酸的协同作用完成。有研究产品在学生群体中使用氨基酸营养液进行输液，目前其效果不能肯定，且存在感染风险。也有利用多巴胺类或氨茶碱类及其效应类似物制备所谓“聪明药”，存在人体形成依赖性问题。实践表明，所谓摄食蔗糖、牛奶、咖啡等提高注意力并不是有效措施。
研究表明，天门冬氨酸、谷氨酰胺和γ-氨基丁酸等氨基酸类物质能够参与中枢神经递质活动，调节体内及脑神经递质多巴胺、去甲肾上腺素、乙酰胆碱酯酶和5-羟色胺的活性。氨基酸主要通过葡萄糖代谢和钠泵作用吸收。葡糖胺、乙酰葡萄糖胺等的氨基能够与氨基酸的羧基通过离子相互作用，适应肠道内的弱碱性环境，缓和氨基酸类物质的吸收。本发明采用葡萄糖胺为调节剂，配以体内天然存在氨基酸及其衍生物，配制成口服制剂，用以调节目标人群或个体的注意力。
发明内容
本发明的目的是提供一种以葡萄糖胺为调节剂的能够增强注意力的制剂,该制剂口服后能够调节目标人群或个体的注意力,本发明的目的是通过以下的技术方法来实现的：
A、选用谷氨酰胺、天门冬氨酸和葡萄糖胺作为原料；
B、原料按比例混合组成口服制剂。
A中所述的选用谷氨酰胺、天门冬氨酸和葡萄糖胺作为原料，其原料葡萄糖胺作为调节剂，与葡萄糖胺具有部分相似结构和调节能力的N-乙酰氨基葡萄糖、甲壳素、N-乙酰基胞壁酸也可部分替代或辅助葡萄糖胺作为调节剂，用于缓和效应强度或调节效应时间；
B中所述的原料按比例混合组成口服制剂，其比例为谷氨酰胺:天门冬氨酸:葡萄糖胺约等于1:2:1且前两种原料的比例可上浮或下浮50%，葡萄糖胺的比例可上浮1～10倍。
具体实施方式
以下实施例用于说明本发明，使其更明确，但决不用来限制本发明的范围，实施例1
1）谷氨酰胺0.1 g、天门冬氨酸0.2 g、葡萄糖胺0.7 g，混合，再与10 g淀粉、0.1 g黄原胶和1 g蜂蜜混合制成丸剂。
Claims (4)
1.一种以葡萄糖醛酸为调节剂的能够强化注意力且缓解神经衰弱的制剂，其制剂的制备在于以下步骤：
A、选用谷氨酰胺、天门冬氨酸和葡萄糖胺作为原料；
B、原料按比例混合组成口服制剂。
2.权利要求1A中所述的选用谷氨酰胺、天门冬氨酸和葡萄糖胺作为原料，其原料葡萄糖胺作为强化注意力的调节剂，用于缓和效应强度或调节效应时间。
3.权利要求2中所述的其原料葡萄糖胺作为强化注意力的调节剂，其调节剂包括与葡萄糖胺具有部分相似结构和作用的N-乙酰氨基葡萄糖、甲壳素、N-乙酰基胞壁酸。
4.权利要求1B中所述的原料按比例混合组成口服制剂，其比例为谷氨酰胺:天门冬氨酸:葡萄糖胺约等于1:2:1且前两种原料的比例可上浮或下降50%，葡萄糖胺的比例可上浮1～10倍。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910617552.XA CN110237062A (zh) | 2019-07-10 | 2019-07-10 | 一种以葡萄糖胺为调节剂的能够增强注意力的制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910617552.XA CN110237062A (zh) | 2019-07-10 | 2019-07-10 | 一种以葡萄糖胺为调节剂的能够增强注意力的制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110237062A true CN110237062A (zh) | 2019-09-17 |
Family
ID=67891616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910617552.XA Pending CN110237062A (zh) | 2019-07-10 | 2019-07-10 | 一种以葡萄糖胺为调节剂的能够增强注意力的制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110237062A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1400871A (zh) * | 2000-02-14 | 2003-03-05 | 菲仕兰品牌公司 | 谷氨酸和/或谷氨酸前体用于制备治疗或预防肠壁渗透性过高或不期望的渗透性的营养或药物制剂的用途 |
| CN1449283A (zh) * | 2001-06-06 | 2003-10-15 | 太阳化学株式会社 | 用于改善注意力缺乏多动性障碍的组合物 |
| US20120308669A1 (en) * | 2011-05-31 | 2012-12-06 | Smith Jr Gerald Zachary | Chocolate candies fortified with natural amino acids and/or herbal nutrients for relief of insomnia, pms, and difficulty concentrating |
| CN103249407A (zh) * | 2010-10-07 | 2013-08-14 | 鹰制药私人有限公司 | 用于治疗抑郁症和其他非感染性疾病的联合疗法 |
| CN109965273A (zh) * | 2019-04-03 | 2019-07-05 | 上海奥医生物医药科技有限公司 | 一种小儿多动症专用型临床营养配方及其制备方法 |
-
2019
- 2019-07-10 CN CN201910617552.XA patent/CN110237062A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1400871A (zh) * | 2000-02-14 | 2003-03-05 | 菲仕兰品牌公司 | 谷氨酸和/或谷氨酸前体用于制备治疗或预防肠壁渗透性过高或不期望的渗透性的营养或药物制剂的用途 |
| CN1449283A (zh) * | 2001-06-06 | 2003-10-15 | 太阳化学株式会社 | 用于改善注意力缺乏多动性障碍的组合物 |
| CN103249407A (zh) * | 2010-10-07 | 2013-08-14 | 鹰制药私人有限公司 | 用于治疗抑郁症和其他非感染性疾病的联合疗法 |
| US20120308669A1 (en) * | 2011-05-31 | 2012-12-06 | Smith Jr Gerald Zachary | Chocolate candies fortified with natural amino acids and/or herbal nutrients for relief of insomnia, pms, and difficulty concentrating |
| CN109965273A (zh) * | 2019-04-03 | 2019-07-05 | 上海奥医生物医药科技有限公司 | 一种小儿多动症专用型临床营养配方及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| 杨乃华编著: "《自然疗法大全》", 31 July 2016, 中医古籍出版社 * |
| 贾竑晓著: "《食物里的"脑黄金"》", 31 January 2016, 中国轻工业出版社 * |
| 赵永才等: "运动与记忆:N-甲基-D-天冬氨酸受体和谷氨酸在学习记忆中的作用", 《中国临床康复》 * |
| 郑子新等主编: "《现代营养全书•营养与健康卷》", 30 June 1999, 四川人民出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020177390A1 (zh) | 一种猴头菌发酵制备含麦角硫因的化妆品原液的方法 | |
| TWI301069B (en) | Edible tremella polysaccharide for skin care | |
| CN1852904A (zh) | 持久力增强剂 | |
| CN107929166A (zh) | 一种亲肤按摩油及其制备方法 | |
| US10568827B2 (en) | External dermal agent for reducing yellowish dullness | |
| CN102727412A (zh) | 澳洲坚果青皮浸膏的制备方法及化妆水 | |
| CN103976351A (zh) | 一种增强免疫力改善睡眠的保健食品及其二步发酵制备方法 | |
| CN103948023B (zh) | 一种增强免疫力及改善睡眠的保健食品及其二步发酵制备方法 | |
| CN107348299A (zh) | 一种具有护肝解酒功效的固体饮料 | |
| CN106377463A (zh) | 一种不含防腐剂的保湿爽肤水组合物 | |
| KR20160114980A (ko) | 아마씨에서 추출한 단백 다당체, 치아씨에서 추출한 단백 다당체 및 폴리글루탐산을 유효성분으로 함유하는 화장료 조성물 및 그 제조방법 | |
| CN110237062A (zh) | 一种以葡萄糖胺为调节剂的能够增强注意力的制剂 | |
| KR102485612B1 (ko) | 콜라겐의 흡수 및 콜라겐의 합성을 촉진하는 조성물 | |
| EP2600881B1 (en) | Natural medicinal compound | |
| CN108078868B (zh) | 一种用于护肤品的抗过敏组合物 | |
| CN108685097B (zh) | 黄菇茑在抗衰老中的应用 | |
| CN111096937A (zh) | 一种含多元植物成分的化妆品防腐剂及其应用 | |
| CN111870558B (zh) | 一种抑制透明质酸酶活性的组合物及皮肤护理产品 | |
| Goloshvili et al. | Characterization of grape seed extracts of native to Georgia varieties of Vitis vinifera L | |
| CN111529456A (zh) | 一种诺丽果植物日用面膜 | |
| CN104642853A (zh) | 一种有机保健蜂蜜 | |
| JP7214328B1 (ja) | 皮膚常在菌叢改善剤及び皮膚外用組成物 | |
| CN106344629A (zh) | 一种崖柏浸泡液及其制备方法 | |
| CN104138395B (zh) | 白囊耙齿菌在制备耐缺氧药物中的用途 | |
| CN104152320B (zh) | 一种苦竹酒及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |
|
| RJ01 | Rejection of invention patent application after publication |